This is a phase 2 trial comparing metastasis-directed therapy (MDT), either surgery or stereotactic body radiotherapy, and surveillance for prostate cancer patients with oligometastatic recurrent disease after primary curative therapy.
Previously reported 3-year results showed better androgen deprivation therapy-free survival with MDT than surveillance.
5-year data were presented by Dr Piet Ost (Ghent University Hospital, Belgium) at ASCO GU 2020, confirming the potential of MDT in prostate cancer.